Filing Flows › Comparisons › SEPN vs VRDN
Septerna vs Viridian Therapeutics: SEPN and VRDN compared
Septerna is the larger company: $26.7M of revenue in its latest quarter (Q2 2026) against $25.8M for Viridian Therapeutics (Q3 2026). Septerna is growing faster (225× against -64% a year earlier). Septerna is more profitable, with an operating margin of -62.9% against -401.8%.
Where the money goes: SEPN and VRDN
Septerna (SEPN) · Q2 2026
Septerna, Q2 2026: revenue $26.7M (225× year over year), operating margin -62.9%, net loss $13.0M, operating cash flow −$22.2M. The chart follows the revenue to costs, profit and cash.
Viridian Therapeutics (VRDN) · Q3 2026
Viridian Therapeutics, Q3 2026: revenue $25.8M (-64% year over year), operating margin -401.8%, net loss $101M, operating cash flow −$92.8M. The chart follows the revenue to costs, profit and cash.
| Septerna (SEPN) | Viridian Therapeutics (VRDN) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $26.7M | $25.8M |
| Revenue growth, Y/Y | 225× | -64% |
| Operating margin | -62.9% | -401.8% |
| Net earnings | −$13.0M | −$101M |
| Net margin | -48.7% | -393.0% |
| Operating cash flow | −$22.2M | −$92.8M |
Where the revenue comes from
Viridian Therapeutics
- Product revenue, net: $24.7M (96%)
- Collaboration revenue: $956K (4%)
- License revenue: $125K (0%)
Questions
Which is bigger, Septerna or Viridian Therapeutics?
Septerna is the larger company: $26.7M of revenue in its latest quarter (Q2 2026) against $25.8M for Viridian Therapeutics (Q3 2026).
Is Septerna or Viridian Therapeutics growing faster?
Septerna is growing faster (225× against -64% a year earlier).
Which is more profitable, Septerna or Viridian Therapeutics?
Septerna is more profitable, with an operating margin of -62.9% against -401.8%.
More: Septerna earnings · how Septerna makes money · Viridian Therapeutics earnings · how Viridian Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 10, 2026; 10-Q filed Nov 4, 2026). Fiscal quarters can end on different dates. Not investment advice.